NordestgaardBGChapmanMJHumphriesSEet al.Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J2013; 34: 3478–3490a.
2.
SantosRDGiddingSSHegeleRAet al.Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol2016; 4: 850–861.
3.
CatapanoALGrahamIde BackerGet al.2016 ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2016; 37: 2999–3058.
4.
FouchierSWDallinga-ThieGMMeijersJCet al.Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res2014; 115: 552–555.
5.
ReinerŽ. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol2015; 12: 565–575.
6.
Harada-Shiba M, Ohta T, Ohtake A, et al. Guidance for pediatric familial hypercholesterolemia 2017. J Atheroscler Thromb. Epub ahead of print 6 February 2018. DOI: 10.5551/jat.CR002.
7.
SjoukeBKustersDMKindtIet al.Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J2015; 36: 560–565.
8.
EAS Familial Hypercholesterolaemia Studies CollaborationVallejo-VazAJAkramAet al.Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl2016; 22: 1–32.
9.
SteinEADannEJWiegmanAet al.Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol2017; 70: 1162–1170.
10.
VuorioAKuoppalaJKovanenPTet al.Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev2017; 7: CD006401–CD006401.
11.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis2016; 23: NP1–NP96.
12.
KustersDMWiegmanAKasteleinJJet al.Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res2014; 114: 307–310.
13.
RaitakariOTJuonalaMRönnemaaTet al.Cohort profile: The cardiovascular risk in Young Finns Study. Int J Epidemiol2008; 37: 1220–1226.
14.
ReinerŽ. Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ Res2014; 114: 233–235.
15.
ReinerŽ. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol2015; 12: 565–575.
16.
Buonuomo PS, Macchiaiolo M, Leone G, et al. Treatment of homozygous familial hypercholesterolemia in pediatric patients: A monocentric experience. Eur J Prev Cardiol. 2018; 25: 1098–1105.
17.
StefanuttiCDi GiacomoSVivenzioAet al.Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr2001; 90: 694–701.
18.
DumićMUroicASFrancetićIet al.Three-year-old boy – a homozygote for familial hypercholesterolemia. Lijec Vjesn2007; 129: 130–133.
19.
KayikciogluMTokgozogluLYilmazMet al.A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis2018; 270: 42–48.
20.
RaalFJBraamskampMJSelveySLet al.Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol2016; 10: 860–869.
21.
ThomasGSCromwellWCAliSet al.Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol2013; 62: 2178–2184.
22.
MartinezMBrodlieSGriesemerAet al.Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia. Am J Cardiol2016; 118: 504–510.
23.
ReinerŽ. PCSK9 inhibitors – past, present and future. Expert Opin Drug Metab Toxicol2015; 11: 1517–1521.
24.
PećinIHartgersMLHovinghGKet al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
25.
ReinerŽ. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis2018; 270: 187–188.
26.
RaalFJHonarpourNBlomDJet al.Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet2015; 385: 341–350.
27.
HovinghGKGoldbergACMoriartyPM. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit. J Clin Lipidol2017; 11: 602–616.
